Carcinoma, Squamous Cell Clinical Trial
Official title:
Phase I Clinical Trial of Hyperbaric Oxygen Combined With Radiation and Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This research is being done because we do not know the best treatment for advanced Squamous
Cell Carcinoma of the Head and Neck. These cancers have been treated with a combination of
surgery, radiation and chemotherapy in varying combination. When the tumor is inoperable,
radiation therapy is used with or without chemotherapy in the hope of curing the tumor.
Recently, it has become recognized as generalized knowledge that cancer cells are hypoxic
(low oxygen concentration). Because of the low oxygen concentrations, many cancer treatments
have not been successful. The theory behind this study is to give oxygen to patients prior
to chemotherapy and radiation in hopes of generating greater results in killing cancer
cells. The purpose of this study has two main objectives. The primary objective is to
determine patient tolerance to each arm of the trial.
The second objective is to determine the feasibility of treatment delivery and acute
toxicities associated with each regimen.
It is our intention to undertake a randomized and controlled trial should this Phase I trial
prove successful in terms of patient tolerance.
The goal of this study is to see if patients can tolerate HBO therapy up to five days a
week.
Three patients in Arm 1 (HBO on Monday and Friday) will be observed throughout their course
of concomitant radiation, chemo and hyperbaric therapy. If these patients appear to tolerate
this protocol well, and no adverse effects that can be directly attributed to HBO are
observed, then three more patients will be recruited for Arm 2 (HBO on Monday, Wednesday,
and Friday). If again these patients appear to tolerate this protocol well, and no adverse
effects that can be directly attributed to HBO are observed, then a third group of three
patients will be recruited for Arm 3 (HBO Monday through Friday).
If Grade IV acute toxicity is reported for a single patient in any of the arms, 3 more
patients will be recruited in the same arm. If no further adverse events occur, the protocol
progresses to the next arm. If Grade IV acute toxicity is observed even a single patient,
the study will be stopped.
Tumor and/or lymphatic tissue specimens will be obtained prior to starting treatment. Tumor
tissue specimens will be analyzed to determine whether there is a predictive susceptibility
of tumors to HBO sensitization using currently defined biomarkers known to correlate with
survival.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02743832 -
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT00389727 -
Simultaneous Integrated Boost (SIB)- IMRT
|
Phase 2 | |
Recruiting |
NCT02328391 -
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
|
N/A | |
Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
Completed |
NCT00534950 -
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
|
N/A | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01362127 -
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
|
Phase 2 | |
Completed |
NCT00240682 -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
|
Phase 2 | |
Terminated |
NCT02254044 -
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
|
Phase 1 | |
Active, not recruiting |
NCT00829192 -
Phase II AK Study in Organ Transplant Patients
|
Phase 2 | |
Completed |
NCT00539630 -
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
|
Phase 3 | |
Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Not yet recruiting |
NCT06094829 -
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
|
||
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Active, not recruiting |
NCT02664935 -
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 |